Zinc in innate and adaptive tumor immunity by John, E et al.
REVIEW Open Access
Zinc in innate and adaptive tumor immunity
Erica John1, Thomas C Laskow1, William J Buchser1, Bruce R Pitt2, Per H Basse3, Lisa H Butterfield4, Pawel Kalinski1,
Michael T Lotze1*
Abstract
Zinc is important. It is the second most abundant trace metal with 2-4 grams in humans. It is an essential trace
element, critical for cell growth, development and differentiation, DNA synthesis, RNA transcription, cell division,
and cell activation. Zinc deficiency has adverse consequences during embryogenesis and early childhood develop-
ment, particularly on immune functioning. It is essential in members of all enzyme classes, including over 300 sig-
naling molecules and transcription factors. Free zinc in immune and tumor cells is regulated by 14 distinct zinc
importers (ZIP) and transporters (ZNT1-8). Zinc depletion induces cell death via apoptosis (or necrosis if apoptotic
pathways are blocked) while sufficient zinc levels allows maintenance of autophagy. Cancer cells have upregulated
zinc importers, and frequently increased zinc levels, which allow them to survive. Based on this novel synthesis,
approaches which locally regulate zinc levels to promote survival of immune cells and/or induce tumor apoptosis
are in order.
“Finding a potent role for zinc in the regulation of autop-
hagic PCD establishes zinc deprivation as a universal
cell death signal, regardless of which route of degrada-
tion–apoptotic or autophagic –is chosen by cells.”
Andreas Helmersson, Sara von Arnold, and Peter V.
Bozhkov. The Level of Free Intracellular Zinc Mediates
Programmed Cell Death/Cell Survival Decisions in Plant
Embryos. Plant Physiol. 2008 July; 147 (3): 1158-1167.
“It’s a business. If I could make more money down
in the zinc mines I’d be mining zinc.” Roger Maris
(American professional Baseball Player. 1934-1985)
“We have everything but the kits in zinc.” Albert
Donnenberg, PhD (Flow Cytometrist, UPSHS) 2009
Biological Role of Zinc
Zinc is the second most abundant metal in organisms
(second only to iron), with 2-4 grams distributed
throughout the human body. Most zinc is found in the
brain, muscle, bones, kidney, and liver, with the highest
concentrations in the prostate and parts of the eye. It is
the only metal that is a coenzyme to all enzyme classes
[1-3]. A biologically critical role for zinc was first
reported in 1869, when it was shown to be required for
the growth of the fungus, Aspergillus niger [4]. In 1926,
zinc was found to be required for the growth of plants
[5], and shortly thereafter, its first function in animals
was demonstrated [6-8]. Now, zinc has been shown to
be important also in prokaryotes [9]. In the last half-
century the consequences of zinc deficiency have been
recognized.
Zinc is a biologically essential trace element; critical
for cell growth, development and differentiation [10]. It
is required for DNA synthesis, RNA transcription, cell
division, and cell activation [11], and is an essential
structural component of many proteins, including sig-
naling enzymes and transcription factors. Zinc is
required for the activity of more than 300 enzymes,
interacting with zinc-binding domains such as zinc fin-
gers, RING fingers, and LIM domains [12-14]. The
RING finger domain is a zinc finger which contains a
Cys3HisCys4 amino acid motif, binding two zincs, con-
tains from 40 to 60 amino acids. RING is an acronym
specifying Really Interesting New Gene. LIM domains
are structural domains, composed of two zinc finger
domains, separated by a two-amino acid residue hydro-
phobic linker. They were named following their discov-
ery in the proteins Lin11, Isl-1 and Mec-3. LIM-domain
proteins play roles in cytoskeletal organization, organ
development and oncogenesis. More than 2000 tran-
scription factors have structural requirements for zinc to
bind DNA, thereby revealing a critical role for zinc in
gene expression.
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Zinc is required for both normal cell survival (as above)
and for cell death via its role in apoptosis. We propose
that zinc may also regulate autophagy and other forms of
survival due to its early sensitivity to cell stress. Thus,
zinc could play a central role, regulating apoptosis and
autophagy as well as immune cell function. Cancer cells
are continuously stressed (genomic stress, ER stress,
nutrient stress, oxidant stress, etc) and selected for survi-
val (likely by autophagy). Here we review the current stu-
dies surrounding zinc, and propose that zinc has a
spectrum of effects on cell death and survival, where zinc
depletion induces cell death via apoptosis (or necrosis if
apoptotic pathways are blocked) while sufficient zinc
levels allows maintenance of cell survival pathways such
as autophagy and regulation of reactive oxygen species.
Cancer cells have upregulated zinc importers, and most
frequently increased zinc levels, which allow them to sur-
vive. Based on these notions, means to locally regulate
zinc levels to promote survival of immune cells and pro-
mote tumor apoptosis are in order.
Dietary Zinc and Deficiency
Red meat is the primary sources of zinc for most Amer-
icans. The already low amount of zinc in vegetables is
further chelated by phytates and is therefore not as
available for absorption. Nuts, and fruits, whole grain
bread, dairy products, and fortified breakfast cereals are
other sources of zinc. Oysters have the highest zinc per
serving of any common food [15,16].
Zinc is taken up primarily in the proximal small intes-
tine, and depends heavily on ZIP4. Once transported
through the enterocytes and into the blood, zinc binds
to albumin, transferrin, a-2 macroglobulin, and immu-
noglobulin G, and travels to the liver where the zinc is
stored in hepatocytes until it is released back into the
blood to again bind carrier molecules and travel to the
tissues where zinc intake will be regulated by zinc
import and transport proteins [17].
Over one billion people in developing countries are
nutritionally deficient in zinc [18]. Zinc deficiency is
associated with a range of pathological states, including
skin changes, loss of hair, slowed growth, delayed
wound healing, hypogonadism, impaired immunity, and
brain development disorders [6,10,19], all of which are
reversible with zinc supplementation. Zinc deficiencies
occur as a result of malabsorption syndromes and other
gastrointestinal disorders, chronic liver and renal dis-
eases, sickle cell disease, excessive alcohol intake, malig-
nancy, cystic fibrosis, pancreatic insufficiency,
rheumatoid arthritis, and other chronic conditions
[18,20-25]. In humans, acrodermatitis enteropathica-like
eruptions are commonly found with zinc deficiency [26].
These pathological states and the associated zinc defi-
ciencies are linked to increased infection and prolonged
healing time, both of which are indicators of compro-
mised immunity. In developing countries, previously
pervasive conditions such as diarrhea [27] and lower
respiratory illness [28] are associated with low zinc.
Unfortunately, quantifying human zinc to identify defi-
ciency and preventing zinc toxicity (due to excess sup-
plementation) is an ongoing challenge [29]. These
findings suggest a role for zinc in immune cell homeos-
tasis in vivo [30,31].
A Signaling Ion
Zinc may act as a signaling molecule, both extracellularly
(as in neurotransmitters) and intracellularly (as in cal-
cium second-messenger systems). In nerve cells, zinc can
be found in membrane-enclosed synaptic vesicles, from
which it is released via exocytosis to bind ligand gated
ion channels (such as NMDA receptors, Ca2+-permeable
AMPA/kainite receptors, and voltage-dependent Ca2+
channels (VDCC)), activating postsynaptic cells [32].
Additionally, changes in the concentration of intracellular
free zinc control immune cell signal transduction by reg-
ulating the activity of major signaling molecules, includ-
ing kinases (PKC, LCK), phosphatases (cyclic nucleotide
phosphodiesterases and MAPK phosphatases), and tran-
scription factors (NFkB).
In T cells, zinc treatment stimulates the kinase activity
of PKC, its affinity to phorbol esters, and its binding to
the plasma membrane and cytoskeleton [33], while zinc
chelators inhibit the induction of these events [34]. Zinc
ions also promote activation of LCK, a Src-family tyro-
sine kinase, and its recruitment to the T cell receptor
complex [35]. The interaction of LCK with CD44 is also
zinc dependent [36]. The release of zinc from lysosomes
also appears to promote T-cell proliferation in response
to IL-2R activation. Here, zinc causes its effect through
the ERK pathway, possibly by inhibiting the depho-
sphorylation of MEK and ERK [37]. Additionally, zinc
regulates inflammatory signaling in monocytes treated
with lipopolysaccharide (LPS), interacting with cyclic
nucleotide phosphodiesterases and MAPK phosphatases
[38-40]. NFkB is a transcription factor involved in cellu-
lar responses to stressful stimuli including cytokines,
free radicals, ultraviolet irradiation, oxidized LDL, and
bacterial or viral infection that plays a key role in regu-
lating the immune response [41]. Zinc regulates
upstream signaling pathways leading to the activation of
this transcription factor [38], as well as potentially regu-
lating NFkB itself [42]. Interestingly, peripheral blood
mononuclear cells (PBMC) from zinc-deficient elderly
individuals show impaired NFkB activation and dimin-
ished interleukin (IL-2) production in response to sti-
mulation with the mitogen phytohemagglutinin (PHA),
corrected by in vivo and in vitro supplementation of
zinc [43].
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In studies measuring changes in intracellular ions such
as calcium and magnesium, the tools used are partially
sensitive to zinc as well. Accurate measurement of intra-
cellular zinc requires indicators with high zinc selectiv-
ity. Currently, the single wavelength dye FluoZin-3
(Invitrogen) responds to small zinc loads, is insensitive
to high calcium and magnesium ions, and is relatively
unaffected by low pH or oxidants [44]. It is noteworthy
that FluoZin-3 fluorescence is non-ratiometric and thus
precludes a precise quantitative determination of labile
zinc, a long sought after goal. Measuring “free zinc” is
complicated by the relative abundance of unoccupied
high-affinity binding sites in most cells. Correctly ascer-
taining free zinc would depend on several factors,
including the buffering capacity and the dissociation
constant of the zinc chelating agent [45,46].
Zinc and the Immune Response
Zinc deficiency affects multiple aspects of innate and
adaptive immunity, the consequences of which in
humans include thymic atrophy, altered thymic hor-
mones, lymphopenia, and compromised cellular-and
antibody-mediated responses that result in increased
rates and duration of infection. Zinc deficiency also
plays a role in the immunosenescence of the elderly
[47]. Changes in gene expression for cytokines, DNA
repair enzymes, zinc transporters, and signaling mole-
cules during zinc deficiency suggest that cells of the
immune system are adapting to the stress of suboptimal
zinc [48]. Furthermore, oral zinc supplementation
improves immunity and efficiently down-regulates
chronic inflammatory responses [34]. These general
findings suggest that zinc is critical for normal immune
cell function, whereby zinc depletion causes immune
cell dysfunction, and zinc supplementation can either
restore function in the setting of dysfunction or improve
normal immune cell function [49].
Zinc and Adaptive Immunity
The adaptive immune response is based on two groups
of lymphocytes, B cells that differentiate into immuno-
globulin secreting plasma cells and thereby induce
humoral immunity, and T cells that mediate cytotoxic
effects and helper cell functions of cell mediated immu-
nity [34]. The known interactions of zinc and the
immune system are categorized in Table 1 and Table 2.
Both responses depend on the clonal expansion of cells
following recognition of their cognate antigen.
Zinc deficiency adversely affects lymphocyte prolifera-
tion. Zinc deficient conditions are associated with ele-
vated glucocorticoids, which cause thymic atrophy and
accelerate apoptosis in thymocytes, thereby reducing
lymphopoiesis [50,51]. In murine studies, zinc-deficient
diets cause substantial reductions in the number of CD4
+ and CD8+ thymocytes with the observation. Naïve
cells sustain high levels of apoptosis in response to zinc-
deficiency-induced elevated levels of glucocorticoids.
Mature CD4+ and CD8+ T cells are resistant to zinc
deficiency and can survive thymic atrophy, possibly
because of higher levels of the anti-apoptotic protein
BCL2 [48,52]. Interestingly, myelopoiesis is preserved in
zinc deficiency, thereby sustaining some aspects of
innate immunity.
Arguably the most prominent effect of zinc deficiency
is a decline in T cell function that results from multiple
causes. First, thymulin, a hormone secreted by thymic
epithelial cells that is essential for the differentiation
and function of T cells, requires zinc as a cofactor and
exists in the plasma in a zinc-bound active form, and a
zinc-free, inactive form [34]. In mice with normal thy-
mic function, zinc deprivation reduces the level of biolo-
gically active thymulin in the circulation [53], thereby
reducing the number of circulating T cells. Zinc supple-
mentation reverses this effect [54,55].
Second, zinc deficiency leads to altered gene expres-
sion in T cells resulting in an imbalance between the
peripheral functions of the Th1 and Th2 cell popula-
tions [10]. Zinc deficiency decreases production of the
Th1 cell cytokines, IFN-g, IL-2, and tumor necrosis
factor (TNF)-a, which play major roles in tumor sup-
pression. These in turn inhibit the functional capacity
of these cells. Production of the Th2 cytokines IL-4,
IL-6, and IL-10 are not affected. Regeneration of CD4+
T lymphocytes and CD8+ CD73+ CD11b-, precursors
of cytolytic T cells, are decreased in zinc-deficient sub-
jects with impaired immune function. An imbalance
between Th1 and Th2 cells, decreased recruitment of
T naive cells, and decreased percentage of T cytolytic
cells are likely responsible for the cell-mediated
immune dysfunction observed in zinc-deficient subjects
[56,57].
Third, in mice, modest zinc deficiencies alter levels of
specific thymic mRNA and proteins even before altera-
tions occur in thymocyte development. Specifically, zinc
deficiency depresses expression of myeloid cell leukemia
sequence-1 (MCL1), the longer product enhancing cell
survival while the alternatively spliced (shorter) form
promoting apoptosis. It also enhances expression of the
DNA damage repair and recombination protein 23B
(RAD23B), and the mouse laminin receptor (LAMR1)
and the lymphocyte-specific protein tyrosine kinase
(LCK) [58], perhaps as secondary effects. Conversely,
zinc supplementation suppresses the development of
Th17 cells in both mouse models and cultured human
and mouse leukocyte cell lines. In vivo and in vitro, zinc
inhibits IL-6 induced phosphorylation of STAT3, and
this observation could in part explain how zinc impedes
the formation of a Th17 response [59].
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Role in Innate Immunity
Natural killer (NK) cells, dendritic cells (DCs), macro-
phages, mast cells, granulocytes, and complement com-
ponents represent central elements of innate immunity.
As observed in adaptive immune cell function, zinc defi-
ciency results in immune dysfunction in innate immu-
nity as well. Specifically, zinc deficiency reduces the lytic
activity of natural killer cells, impairs NKT cell cytotoxi-
city and immune signaling, impacts the neuroendocrine-
immune pathway, and alters cytokine production in
mast cells [60-62]. Zinc supplementation enhances
innate immunity against enterotoxigenic E.coli infection
in children due to increases in C3 complement,
enhanced phagocytosis, and T cell functionality [63].
NK cells
Zinc deficiency reduces NK cell lytic activity in zinc
deficient patients, while zinc supplementation improves
NK cell functions. For example, zinc treatment at phy-
siological doses for one month in elderly infected
patients, increases NK cell cytotoxicity and enhances
recovery of IFN-g production leading to a 50% reduction
in relapse of infection [61]. Additionally, in vitro, zinc
supplementation improves the development of NK cells
from CD34+ cell progenitors via increased expression of
GATA-3 transcription factor [60]. Notably, centenarians
have well-preserved NK cell cytotoxicity, zinc ion bioa-
vailability, satisfactory IFNg production, and preserved
thyroid hormone turnover [62], suggesting the impor-
tance of zinc in maintaining both NK cell function and
the immunologically involved neuroendocrine pathway
in the elderly. Its role in regulating Class I MHC mole-
cules has not been extensively studied, but it does
appear that it is critical for HLA-C interaction with
killer cell Ig-like receptors (KIRs). Interestingly, the
kinetics of the binding of KIR to their respective indivi-
dual Class I MHC ligands is altered significantly in the
presence of zinc, but not other divalent cations. Zinc-
induced multimerization of the KIR molecules may be
critical for formation of KIR and HLA-C molecules at
the interface between the NK cell and target cells [30].
Metallothioneins (MTs), small cysteine-rich proteins
that bind zinc as well as other metal ions, mediate zinc
homeostasis, and are therefore critical to not only NK
function but also other cellular functions. Recent studies
in aging show a novel polymorphism in the MT1A cod-
ing region in MT genes that affects NO-induced zinc
ion release from the protein [64]. Other polymorphisms
in MT genes impair innate immunity, further confirm-
ing a link among zinc, MT, and the innate immune
response during aging.
NKT Cells
NKT cells are a bridge between the innate and the
adaptive immune systems [65], displaying both cytotoxic
abilities as well as providing signals required for driving
the adaptive immune response. Both zinc and MTs
affect NKT cell development, maturation, and function.
In conditions of chronic stress including aging, zinc
release by MTs is limited, leading to low intracellular
zinc bioavailability and subsequent reduced immunity
[31]. Furthermore, during stress and inflammation,
expression of MTs is induced by the pro-inflammatory
cytokines IL-1, IL-6, and tumor necrosis factor (TNF)-a
[66], resulting in further sequestration of zinc by MTs
[67].
Additionally, some zinc finger motifs play an impor-
tant role in the immune response of NKT cells. The
BTB-ZF transcriptional regulator, promyelocytic leuke-
mia zinc finger (PLZF), is specifically expressed in
Table 1 Zinc and Immune Cell Functions
Cell Type Comment References
Macrophages MT-knockout results in defects in phagocytosis and antigen presentation [73]
Dendritic cells Zinc induces maturation and increases surface MHCII [70]
NK cells Zinc increases cytotoxicity and restores IFN-g production [50,52,61]
NKT cells Zinc release from MTs in limited during chronic stress. Stress and inflammation induce MT gene expression, further
sequestering zinc
[31,66,67]
iNKT cells Cells lacking PLZF lack innate cytotoxicity and do not secrete IL-4 and IFN-g [68]
CD4
thymocytes
Zinc deficiency elevates glucocorticoid levels, causing apoptosis and reduced numbers of thymocytes [52,57]
CD4 helper
T cells
Zinc deficiency shifts Th1 to Th2 response via altered cytokine release [10,48,56,176]
CD8
thymocytes
Zinc deficiency results in reduced numbers of thymocytes due glucocorticoid-induced apoptosis [48,52]
T cells Zinc deficiency results in decreased function due reduced biologically active thymulin [53-55]
T reg ?
Mast cells Required for IL-6 and TNF-a production [71,72]
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invariant natural killer T (iNKT) cells (Table 2). In the
absence of PLZF, iNKT cells have markedly diminished
innate cytotoxicity and do not secrete IL-4 or IFN-g fol-
lowing activation [68]. Thus, zinc deficiency causes a
reduction in both innate and adaptive immune function-
ing in NKT cells.
Hormonal Influence
Hormones from the hypothalamic-pituitary-gonadal axis
(i.e. FSH, ACTH, TSH, GH, T3, T4, insulin, and the sex
hormones) directly affect the innate immune response,
interacting with hormone receptors on immune cells,
including NK cells. Hormonally activated NK cells pro-
duce cytokines that mediate adaptive immune responses.
Deficient production of these hormones impairs innate
and adaptive immune response in aging. The beneficial
effects of hormone supplementation on immunity are
mediated in part by enhanced intestinal zinc absorption.
Therefore, zinc is a nutritional factor pivotal in main-
taining the neuroendocrine-immune axis [69].
Dendritic cells (DCs)
DCs are also profoundly affected by zinc. Exposure of
mouse dendritic cells to LPS, a toll-like receptor 4
(TLR4) ligand, leads to a decrease in the intracellular
free zinc concentration and a subsequent increase in
surface expression of MHC Class II (Figure 1), thereby
enhancing DC stimulation of CD4 T cells [70].
Table 2 Zinc and Proteins of Immunological Significance
Protein Immunological Role References
Calcineurin Zinc inhibits Calcineurin activity in Jurkat cells [177]
COX-2 Lung zinc exposure increases COX-2 [178]
Caspases Cytosolic caspase-3 activity is increased in Zn-deficient cells. May be mediated by the cytoprotectant abilities of zinc [110]
E-selectin Zinc deficiency increased E-selectin gene expression [179]
FC epsilon
RI
Mast cell activation downstream of FC epsilon requires zinc [72,180]
HMGB1 3 Cys, 2 His, unknown role of zinc [174]
HSP70 Zinc increased basal/stress-induced Hsp70 in CD3+ lymphocytes [181]
IFN-g ZIP8 influences INF-gamma in T cells [177]
IL-1 b Zinc suppresses IL-1 beta expression in monocytes [39,182]
IL-2 High zinc decreased IL-2 in T cell line, Jurkat cells [183,184]
IL-2R a High zinc decreased IL-2R a in T Cell Line [184]
IL-6 Zinc modulated circulating cytokine in elderly patients [61,185,186]
KIR Zinc is necessary for the inhibitory function of KIRs [187,188]
MCP-1 Zinc modulated circulating MCP-1 in elderly patients [185]
MHC Class
II
There is zinc dependent binding site where super-antigens and peptides bind [189,190]
NFkB NFkB p65 DNA-binding activity increased by zinc deficiency (sepsis). Zinc regulates NFkB. High zinc decreases NFkB
activation in T Cell Line. Zinc activates NFkB in T cell line. IKK gamma zinc finger, can regulate NFkB
[42,179,191,192]
PDE-1,3,4 Zinc reversibly inhibited enzyme activity of phosphodiesterases. [39]
PPAR-a Zinc deficiency down-regulated PPAR-a [184]
Proteasome Zinc can inhibit proteasome [193]
S100
Proteins
RAGE ligands [173]
TLR-2 Zinc limits TLR surface expression [194]
TNF-a Zinc suppresses TNF-a expression in T-Cells, monocytes [39,40,184]
Zinc finger proteins
A20 zinc
finger
Modulates TLR-4 signaling, Inhibits TNF-induced apoptosis [192,195]
DPZF BCL-6 Like Zinc Finger, Immune responses [196]
Gfi1 Antagonizes NFkB p65, Upstream of TNF [197,198]
IKK g Zinc finger that regulates NFkB [199]
PLZF Expressed in iNKT cells. iNKT cells lacking PLZF lack innate cytotoxicity and do not secrete IL-4 or IFN-g [68]
ZAS3 Zinc Finger protein that inhibits NFkB [200]
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Conversely, artificially elevating intracellular zinc levels
suppresses the ability of DCs to respond to LPS. Zinc
suppresses the surface expression of MHC class II
molecules two ways: it inhibits the LPS-induced move-
ment of MHC class II containing vesicles to the cell
surface from the perinuclear region, and it promotes
endocytosis of MHC class II molecules expressed on
the plasma membrane. Zinc down-regulates the
expression of the zinc importer, ZIP6 (see below),
resulting in reduced intracellular zinc concentrations.
Over-expression of ZIP6 suppresses DC expression of
MHC class II (and subsequent stimulation of CD4+ T
cells) [70]. In vivo, injections of LPS or a zinc chelator,
N,N,N,N - tetrakis -2- pyridylmethylethylenediamine
(TPEN), reduce the expression of the ZIP importers
and increase the expression of zinc exporters, thereby
reducing intracellular free zinc and increasing the sur-
face expression of MHC class II. Intracellular zinc traf-
ficking is thus important in DC maturation and
subsequent T-cell activation [70]. While the observed
decrease in intracellular zinc and subsequent enhance-
ment of DC immune signaling may seem contrary to
that observed with other immune cells, it should be
noted that DCs undergo apoptosis following activation
of their lymphocyte target(s) in the secondary lymph
node sites. Therefore, upregulated immune signaling
via MHCII is an effect that is followed by cell death,
which is congruent with the effects of zinc depletion
observed in other immune cell types.
Mast Cells
In mast cells, an increase in intracellular free zinc,
known as the ‘zinc wave’, occurs within minutes of
extracellular stimulation [71]. This rapid response in
mast cells is in contrast to changes observed in intracel-
lular zinc in DCs, which are dependent on transcrip-
tional regulation in zinc transporters and are therefore
observed several hours following stimulation. Zinc defi-
ciency in mast cells prevents translocation of PKC and
downstream events such as the phosphorylation and
nuclear translocation of NFB as well as the down-
stream production of the cytokines IL-6 and TNFa [72].
Additionally, the granules of mast cells (and other
immune cells) have high concentrations of zinc, which
upon release could alter the extracellular milieu as well
as immune, stromal, and epithelial/tumor cell functions.
Macrophages
Macrophages from metallothionein knockout (MT-KO)
mice have defects in phagocytosis, cytokine production,
and antigen presentation [73]. Production of IL-1., IL-6,
IL-10, and IL-12 as well as the expression of CD80,
CD86 and MHC Class II molecules are reduced in
macrophages from MT-KO mice. Therefore, zinc regu-
lation by MTs plays an important role in the regulation
of macrophage immune function. In some studies, zinc
supplementation of human PBMCs increases mRNA
production and subsequent release of the cytokines IL-6,
IL-1b, and TNF-a [74], promoting the recruitment of
leukocytes to the site of infection [34]. Conversely, zinc
treatment suppresses the formation of pro-inflammatory
cytokines [75,76]. It is thought that the effect of zinc is
concentration dependent, and that zinc can be either sti-
mulatory or inhibitory: an increase of intracellular free
zinc induces cytokine production of monocytes in
response to LPS [40], while higher concentrations can
have the opposite effect by inhibiting cyclic nucleotide
phosphodiesterases and subsequently activating protein
kinase A [34,39]. Zinc can also suppress monocyte LPS-
induced tumor necrosis factor (TNF)-a and IL-1b
release, through inhibition of phosphodiesteras-mediated
hydrolysis of cyclic nucleotides into 5′-nucleotide mono-
phosphate and increases of intracellular cGMP levels.
The NO donor s-nitroso-cysteine (SNOC) also inhibits
LPS-induced TNF-a and IL-1b release, and increased
levels of intracellular free zinc [77].
Parenchymal Cells
Zinc has also been shown to be important regulators of
immunity through its impact on non-circulating cells.
Figure 1 Intracellular Zinc Levels Fall During Dendritic Cell
Maturation. After the detection of LPS (Pathogen Associated
PAMPs) by TLR4 and activation of TRIF, zinc importers (ZIPs)
expression is diminished while transporters (ZNTs) expression is
increased. The resulting decrease in intracellular zinc concentration
promotes the surface expression of MHC-II and thus the maturation
of DCs.
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Zinc deficiency promotes sepsis invoked organ damaged
due to its effects in the epithelial cells of most organs
[78]. In the lung parenchyma for example, zinc can act
to diminish inflammation, and promote cell health and
survival [79].
Role in Oncogenesis
Zinc helps to maintain intracellular ion homeostasis and
contributes to signal transduction in most cells. As
such, zinc directly affects tumor cells through its regula-
tory role in gene expression and cell survival, both of
which are controlled at least in part by tumor-induced
alterations in zinc transporter expression, and influences
tumor cells indirectly by affecting the activation, func-
tion, and/or survival of immune cells [77].
Levels of zinc in serum and malignant tissues of
patients with various types of cancer are abnormal, sup-
porting the involvement of zinc in cancer development.
Studies of the role of zinc in malignant diseases have a
long history of contradictory and ill-defined biological
effects [80]. It is clear, however, that serum zinc levels
are reduced in patients with cancers of the breast [81],
gallbladder [82], lung [83], colon, head and neck [84]
and bronchus [83,85,86], and in the leukocytes and
granulocytes of patients with bronchus and colon cancer
[86]. Serum and tumor zinc levels in human cancer are
summarized in Table 3. Interestingly, while serum zinc
levels are low in the setting of most cancers, tumor tis-
sue in breast and lung cancer have elevated zinc levels
when compared with the corresponding normal tissues
[86,87]. Additionally, peripheral tissue surrounding liver,
kidney, and lung metastasis have higher zinc content
than the corresponding normal tissue or the tumor tis-
sue itself [86]. While data of zinc levels in tumor tissue
is limited, it has been widely recognized that ZIP, cellu-
lar zinc importers, are upregulated in most cancers (see
below and Table 4), thereby indicating increased zinc
concentrations in most tumor.
Prostate tumor cells and skin cancer are the exception
to these findings, in that zinc levels are lower in prostate
tumor tissue than in normal prostate cancer [86,88].
Prostate glandular epithelium has the specialized func-
tion of producing and secreting large quantities of
citrate, and thus requires metabolic activities that are
unique to these cells. Zinc accumulation in these cells is
critical to their specialized metabolism. In malignant
prostate cells, the normal zinc-accumulating epithelial
cells undergo a metabolic transformation causing them
to lose the ability to accumulate zinc. Genetic alteration
in the expression of the ZIP1 zinc importer is associated
with a metabolic transformation analogous to the
changes observed in malignant prostate. In fact, ZIP1,
ZIP2, and ZIP3 are down-regulated in prostate cancer
cells, suggesting that changes in intracellular zinc play a
role in tumorigenesis. In a study by Gonzalez et al. [89],
dietary zinc was not associated overall risk of prostate
cancer, but long-term supplemental zinc intake was
associated with reduced risk of advanced prostate can-
cer. Authors note much variability in current studies
correlating zinc and prostate cancer. High extracellular
zinc is also important, since it was shown to induce
cytotoxicity in human pancreatic adenocarcinoma cell
lines. Normal human pancreatic islet cells tolerated high
zinc, making zinc elevation a potential treatment avenue
[90]. Zinc could prevent UVB-induced aging and skin
cancer development through the induction of HIF-
1alpha, a protein that controls the keratinocyte cell
cycle, and is down-regulated by UVB and therefore
involved in UVB-induced skin hyperplasia [91].
HDAC inhibitors are being used as anticancer agents
given their wide range of substrates, including proteins
that have roles in gene expression, cell proliferation, cell
migration, cell death, immune pathways, and angiogen-
esis. There are eleven zinc dependent HDACs in
humans. The synergy of HDAC is with current anti-can-
cer therapies including radiation, anti-metabolites, anti-
microtubule agents, topoisomerase inhibitors, DNA
cross-linking agents, monoclonal antibodies, and EFGR
inhibitors have been the topic of many studies [92].
Other zinc-finger transcription factors may directly
influence tumor formation through the epithelial-
mesenchymal transition. SNAIL, MUC1, ZEB1 are
known to influence the transition away from non-
tumorous epithelial lineages back to the more invasive
lineages, and are effected by zinc changes [93-95].
Zinc levels are directly affected by the tumor microen-
vironment. Pro-inflammatory mast cells are found
within the cancer microenvironment and release
Table 3 Zinc Levels in Tumor Tissue
Cancer Zinc level References
Breast, gallbladder, colon, bronchus, lung Decreased serum zinc [81-83,86]
Liver, kidney, lung Increased zinc in peritumor tissue as compared to both normal tissue and tumor itself [86]
Breast, lung (likely others except prostate) Increased zinc in tumor tissue [86,87]
Prostate Decreased zinc in tumor tissue [86,88]
Head and Neck Increasing zinc improves local free survival, Decreased serum zinc near end of life [84,201]
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granules with high levels of zinc into the surrounding
tissue [77]. Mast cell presence within tumors is thought
to worsen the prognosis of most patients with cancer,
and changes in extracellular zinc affect the cellular
response in the tumor environment. Many cytokines
and growth factors produced in the tumor microenvir-
onment, including IL-6, hepatocyte growth factor, epi-
dermal growth factor, and TNF-a, directly or indirectly
affect the expression of various zinc transporters [96],
thereby changing the intracellular concentrations of zinc
in both tumor cells and neighboring tissues (see follow-
ing section). Furthermore, it is likely that the activities
of many enzymes and transcription factors that require
zinc to function are affected by the altered zinc concen-
trations found within the cancer microenvironment.
Oxidation/reduction reactions in tumors and surround-
ing tissues influence intracellular free zinc concentra-
tions [77] and indeed, zinc levels may be an early
intracellular ‘reporter’ of reactive oxygen species and
subsequent biologic responses.
Zinc Transport and Cancer
Eukaryotic cells have a remarkable ability to regulate the
levels of intracellular zinc. Although zinc is commonly
reported to be femtomolar in concentration, it is actu-
ally found in high picomolar ranges in eukaryotic cells
[45,46,97]. Several proteins, including the ZIP (ZRT-and
IRT-like proteins (SLC39A)), ZNT (Zinc transporter
(SLC30A)), and zinc-sequestering MTs, maintain intra-
cellular zinc homeostasis [98-101]. ZIP members facili-
tate zinc influx into the cytosol from extracellular fluid
or from intracellular vesicles, while ZNT proteins lower
intracellular zinc by mediating zinc efflux from the cell
or influx into intracellular vesicles [98,100]. Zinc seques-
tration is regulated primarily through zinc-dependent
control of transcription, translation, and intracellular
trafficking of transporters [101,102]. Expression levels of
zinc transporters in human tumors correlate with their
malignancy, suggesting that alteration of intracellular
zinc homeostasis can contribute to the severity of cancer
[103-106]. There are at least 14 human ZIP transporters,
which allow zinc influx into the cell [107,108]. Specific
zinc importers are upregulated in most cancer types,
perhaps allowing tumor cells to escape apoptosis and
activate cell survival via autophagic processes. Some
important zinc transporters (ZIPs and ZNTs) are shown
in Table 4 and Figure 2.
Cell Death
Apoptosis is an active, gene-directed, tightly-regulated
process of programmed cell death that involves a series
of cytoskeletal, membrane, nuclear, and cytoplasmic
changes that culminate in condensation and fragmenta-
tion of the cell into apoptotic bodies, which are even-
tually cleared by phagocytosis [109]. Apoptosis is the
major mechanism of cell death in the body, enabling the
removal of excess, mutant, or damaged cells. In contrast
to necrosis, apoptosis deletes cells without release of
their contents that would otherwise provoke and possi-
bly damage neighboring cells and result in an inflamma-
tory response. Apoptosis consumes energy, and involves
signaling pathways originating from the plasma mem-
brane (TNF receptor family molecules including the Fas
receptor ligation or lipid peroxidation), the nucleus
(DNA damage/mutation) or the cytoskeleton (disruption
of microtubules) [110].
The mitochondrion has a major role in the induction,
regulation, and execution of apoptosis. Mitochondria
coordinate apoptosis by channeling various input signals
into a central pathway, which is governed by mitochon-
drial-associated anti-apoptotic (Bcl-2) and pro-apoptotic
(Bax) families of regulators and by providing an environ-
ment for the proteolytic events that trigger processing and
activation of various members of the caspase enzyme
family [111]. Action of the caspases leads to morphological
changes such as cell shrinkage, condensation and fragmen-
tation of both the cytoplasm and nucleus and formation of
membrane-enclosed apoptotic bodies [111,112].
Apoptosis is tightly regulated and its deregulation is
central to the pathogenesis of a number of diseases–
increased in neurodegenerative disorders, AIDS, and
diabetes mellitus, and decreased in autoimmune disease
and neoplastic malignancies [113,114]. As such, the fac-
tors that regulate the execution phases of apoptosis are
of great interest as potential therapies. One of these reg-
ulators is zinc.
Table 4 Zinc Transporters (Importers) and Cancer
Cancer Transporter Comment References
Erythroleukemia ZIP1 In the vesicular compartment and partly in the ER in adherent cells [99]
Squamous cell carcinoma ZIP2 mRNA is induced by contact inhibition and serum starvation [202]
Prostate ZIP1, ZIP2, ZIP3 Down-regulated in malignant cells [203]
Pancreas ZIP4 Over-expression is linked to increased cell proliferation [106]
Breast ZIP6, ZIP10 Expression is linked to metastasis to lymph node [204,205]
Tamoxifen resistant breast cancer ZIP7 Increased levels results in increased growth and invasion [182,206,207]
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Zinc and Apoptosis
At the beginning of this decade Truong-Tran et al.
assembled a core picture of zinc’s role in apoptosis
[109]. In this picture, the presence of zinc is anti-apop-
totic, and this apoptotic effect has two aspects. Firstly,
zinc may directly protect cells against oxidative damage.
An example of this mechanism would be the thiolate
complexes that zinc forms with sulfhydryl groups in
proteins. This complex is strong enough to protect and
prevent protein oxidation by ROS, but is still reversible.
Secondly, evidence suggested that zinc might inhibit cas-
pase-3 activation, perhaps, again, through forming a
complex with a sulfhydryl group, in this case preventing
proteolysis. There have also been some studies which
imply the contrary, due to zinc’s ability to inhibit impor-
tant ROS-protective enzymes [115,116]. In mouse DCs,
zinc induces apoptosis by stimulating the formation of
ceramide [117]. Similar events are observed in erythro-
cytes, where zinc induces secretory sphingomylenase,
which produces ceramide leading to apoptosis [118].
Although high concentrations of zinc may trigger cell
death by apoptosis or necrosis [119-122]in many set-
tings, zinc is a physiological suppressor of apoptosis.
There are two major anti-apoptotic mechanisms of zinc:
it directly influences apoptotic regulators, especially the
caspase family of enzymes, and it may prevent oxidative
damage and damage induced by toxins, thereby suppres-
sing the caspase activating pathways and apoptosis.
These two mechanisms are closely related since a
decline in intracellular zinc below a critical level may
not only trigger pathways leading to caspase activation
via increased oxidative stress, but may also directly facil-
itate the process by which the caspases are activated
[109].
Zinc deficiency-induced apoptosis in vitro and in vivo
displays all of the fundamental characteristics of apopto-
sis, including DNA and nuclear fragmentation, chroma-
tin condensation and apoptotic body formation [123],
indicating that apoptosis is directly related to the
decrease in intracellular zinc. Zinc deficiency decreases
cell proliferation and increases apoptosis in neuroblas-
toma IMR-32 cells. In these cells, low zinc arrests the
cell cycle at G0/G1 phase, and induces apoptosis
through the intrinsic pathway [124]. Specifically, cytoso-
lic caspase-3 activity is increased in zinc deficient cells,
and zinc suppresses caspase-3 activity and apoptosis in
rats in vivo [125]. Taken together, this demonstrates
that zinc deficiency-induced apoptosis is dependent on
Figure 2 Localization and transport of zinc in a mammalian cell. Cellular localization and function of ZIP and ZNT zinc transporter family
members. Arrows indicate the direction of zinc mobilization. ZIP1, 2 and 4 are induced in zinc deficient conditions, while ZNT-1 and 2 members
are induced by zinc administration. In general zinc efflux is associated with enhanced susceptibility to apoptosis and higher levels with
protection/autophagy.
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caspase-3 activation. Interestingly, in zinc deficiency, the
frequency of apoptotic cells is significantly increased in
specific tissues, including the intestinal and retinal pig-
mented epithelium, skin, thymic lymphocytes, testis and
pancreatic acinar cells [126,127] and neuroepithelium
[128]. The importance of these observed localizations
has yet to be elucidated.
In 2010, our understanding of the role of zinc has
progressed to the point where we understand zinc’s role
in apoptosis to involve both direct effects on mitochon-
dria and the nucleus as well as on various factors and
signaling pathways within and between the cytosol,
mitochondria, and nucleus. We also know that within
some cell types including neurons, glial cells, and pros-
tate epithelial cells, zinc may be pro-apoptotic [129].
Still, many of the precise mechanisms through which
zinc regulates apoptosis and proliferation remain to be
elucidated. Interestingly a pro-apoptotic compound
which increases the conversion of pro-caspase 3 to the
active caspase 3 form was found to operate through the
sequestration of the zinc that inhibits cleavage of the
pro-caspase 3 [130].
Many animal studies have linked zinc deficiency with
enhanced rates of oxidative damage [131-133]. Zinc sup-
plementation also protects against intracellular oxidative
damage. Zinc depletion increases the rate of apoptosis,
and there is a synergy in the induction of apoptosis
between zinc depletion and other apoptotic inducers
such as colchicine, tumor necrosis factor and HIV-1 Tat
protein [134,135]. Therefore, major reductions in intra-
cellular zinc can directly induce apoptosis, while smaller
decreases may increase cell susceptibility to apoptosis by
other toxins.
Zinc is a cytoprotectant, and as such it protects and
stabilizes proteins, DNA, cytoskeleton, organelles, and
membranes [136], reminiscent of survival factors asso-
ciated with autophagy. For instance, axons and dendrites
exposed to zinc chelators (TPEN and zinquin) slowly
“die back”, due to metabolic lack of neuronal ATP,
which can be resolved with addition of NAD [137]. Zinc
can also up-regulate MT, which stabilize lysosomes and
decrease apoptosis resulting from oxidative stress, due
to increases in autophagy [138]. Cytoprotective zinc is
most likely the exchangeable (loosely bound or tightly
bound but kinetically labile) zinc pools [97,134,136].
Zinc protects sulfhydryl groups in proteins from oxida-
tion by forming strong, reversible, thiolate complexes,
and as such provides protection to enzymes with essen-
tial thiols such as tubulin, where sulfhydryls are required
for polymerization into microtubules [139,140]. As such,
zinc is a stabilizer of microtubules, and microtubule dis-
ruption occurs in zinc deficiency [141], oxidative stress
[142] and in the early stages of apoptosis [143]. It is also
important to note that TPEN itself or TPEN-Zinc
complexes may actually be the cause of increased apop-
tosis in some of these experiments [144].
Supplementing cells with exogenous zinc in vitro
decreases the susceptibility of cells and tissues to spon-
taneous or toxin-induced apoptosis. In several studies,
zinc-supplemented animals have increased resistance to
apoptotic inducers. For example, zinc has protective
effects against whole body irradiation in mice [145],
neuronal apoptosis following transient forebrain ische-
mia in the hippocampus of primates [146], and apopto-
sis of the anterior and stromal keratinocytes in the eye
following superficial keratectomy in rabbits [147]. PBLs
pretreated with zinc are resistant to Cr(III)(phe)3
induced apoptosis. This reduced apoptosis correlated
with decreased ROS production in cells pretreated with
zinc [148]. Zinc blocks apoptosis induced by all apopto-
sis-inducing treatments tested, indicating that it sup-
presses a central pathway [127,135,149]. Monocytes in
chronic HIV viremia are resistant to apoptosis. Expres-
sion of MTs, which are highly involved in cellular zinc
metabolism, and ZIP8 zinc importer are up-regulated in
these monocytes. Increased intracellular zinc, therefore,
may play a role in the apoptotic resistance seen in
monocytes during HIV viremia [150].
There are several issues, however, with zinc supple-
mentation studies and their interpretation. There is
relatively poor uptake of ionic zinc across the plasma
cell membrane, and mM concentrations of zinc can
cross-link proteins nonspecifically, rendering interpre-
tation difficult. Exogenous zinc driven into cells with
an ionophore, such as pyrithione, has resolved many of
the zinc uptake issues, but presents a secondary pro-
blem. Many zinc ionophores act on other cellular
cations such as calcium and magnesium [151]. Addi-
tionally, using ionophores may produce much higher
intracellular zinc levels than would occur in vivo.
Metabolically available zinc is distributed non-uni-
formly throughout the cell with nM-pM concentrations
in the cytosol and up to mM concentrations within
vesicles [97]. It is unknown whether zinc supplementa-
tion affects the same pools and apoptotic targets as
does zinc depletion.
Zinc, Apoptosis and Cancer
Role in Necrosis
In some cells, zinc deprivation results in necrosis. The
reason for this has not yet been elucidated, but may
depend on the functional state of activated caspases. In
TPEN-induced zinc-deficient human renal cell carci-
noma cell lines lacking caspases-3, -7, -8 and -10 died
by necrosis rather than apoptosis [152]. In these cases,
zinc may not regulate apoptosis, but rather function as a
cytoprotectant that, in zinc-deficient conditions, leaves
the cell vulnerable to apoptosis and necrosis.
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Zinc and Autophagy
Normal cellular growth and development require a bal-
ance between protein synthesis and degradation. Eukar-
yotic cells have two major avenues for degradation: the
proteasome and autophagy [153]. Autophagy, literally
‘self-eating’, is involved in the bulk degradation of long-
lived cytosolic proteins and organelles, whereas the ubi-
quitin-proteasome system degrades specific short-lived
proteins. Autophagy is a highly conserved process in
eukaryotes in which excess or aberrant organelles and
their surrounding cytoplasm are sequestered into dou-
ble-membrane vesicles and delivered to the lysosome for
breakdown and eventual recycling of the resulting
macromolecules. There are three types of autophagy,
the first of which, chaperone-mediated autophagy, is a
mechanism that allows the degradation of cytosolic pro-
teins that contain a particular pentapeptide consensus
motif [154,155]. The two other types of autophagy,
macro-autophagy and microautophagy, involve dynamic
membrane rearrangements and terminate at the lyso-
some [156,157] with fusion and degradation. Microauto-
phagy is a direct engulfment of cytoplasm at the surface
of the degradative organelle by protrusion, septation,
and/or invagination of the membrane, while macroauto-
phagy involves sequestering cytoplasm into a double-
membrane cytosolic vesicle, the autophagosome [153].
Autophagosomes fuse with the lysosome, the contents
are degraded, and the macromolecules recycled.
Autophagy has an important role in various biological
events such as adaptation to changing environmental
conditions [158,159], cellular remodeling during devel-
opment and differentiation, and determination of life-
span [160]. Autophagy may play a protective role
against the progression of some human diseases, includ-
ing cancer, muscular disorders, and neurodegeneration,
such as Huntington’s, Alzheimer’s, and Parkinson’s dis-
eases [160-162], and acts as a cellular defense mechan-
ism to prevent infection by certain pathogenic bacteria
and viruses [162-164]. Autophagy is involved in some
forms of cell death and might contribute to the pathol-
ogy of associated diseases [157,165].
Endogenous zinc levels appear to be critical to induce
autophagy under conditions of oxidative stress in astro-
cytes. Autophagy is a necessary preceding event for lyso-
somal membrane permeabilization and cell death in
oxidative injury [166]. When autophagy is induced in
astrocytes, the number of autophagic vacuoles positive
for LC3 (microtubule-associated protein 1 light chain 3),
a marker of autophagy, increases, and levels of labile
zinc increase in autophagic vacuoles as well as in the
cytosol and nuclei. Interestingly, chelation of zinc with
TPEN decreases the number of autophagic vacuoles in
autophagy-induced astrocytes, similar to the effects
observed with autophagy inhibitors (3-methyladenine,
bafilomycin-1). Conversely, exposure to zinc increases
the number of autophagic vacuoles. Taken together,
these findings suggest that zinc is critical to autophagy.
Possibly related to zinc’s role in autophagy, ethambutol,
an anti-tuberculosis agent, can cause irreversible vision
loss, associated with severe vacuole formation in cul-
tured retinal cells. In ethambutol-treated cultured retinal
cells, almost all ethambutol-induced vacuoles contained
high levels of labile zinc. Intracellular zinc chelation
with TPEN blocks both vacuole formation and zinc
accumulation in the vacuole, and inhibits lysosomal acti-
vation and lysosomal membrane permeabilization [167].
Although there are examples of zinc’s effect on autop-
hagy in bacteria and yeast [168], it is not as clear how
these can be translated to mammals. Zn mediates
tamoxifen-induced autophagy in breast cancer cells
[169], hippocampal neurons [170], retinal cells [167],
and in astrocytes via increases in oxidative stress and
induction of lysosomal membrane permeabilization
[171]. The newer studies have used animals deficient in
metallothionein to study the changes and importance of
zinc. Again, autophagy is now seen as a mechanism that
tumor cells use to promote their survival, even in face
of potent chemotherapies [169].
The alterations of free zinc concentration and zinc
transporters in maturing dendritic cells suggest another,
as yet unexplored intersection between zinc regulation
and autophagy. After all, the activation of autophagy
mechanisms is a second defining feature of DC matura-
tion and effective MHC-II antigen loading [172].
Summary
Significant disorders of great public health interest are
associated with zinc deficiency. The amelioration of a
number of common conditions with zinc supplementa-
tion in the context of malnutrition has underscored the
importance of this micronutrient. Rapid advances in
molecular biology and genetics have revealed the com-
plexities in zinc homeostasis and the attendant patho-
physiology of mutations in critical genes affecting
usually well controlled intra-and extracellular levels of
zinc. It is apparent that a labile pool of zinc contributes
to a myriad of cell signaling processes providing critical
insight into the role of zinc in health and disease. In the
immune system, we now know that this pool can affect
function, differentiation, maturation and cell death path-
ways in critical immunocytes thereby contributing to
many aspects of innate and adaptive immunity. Similar
observations are apparent in tumor cells and the critical
contribution of immune cells in the microenvironment
and pathogenesis of cancer underscores the potential
connection between zinc homeostasis and oncology.
Manipulating zinc levels in adoptively transferred
immune cells thus may be an interesting and important
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means to alter their function, and promote either toler-
ance or immunity. Though biologically significant, exo-
genous zinc may be too blunt a tool for targeting some
zinc dependent cellular processes. Drugs and treatments
capable of targeting zinc levels of specific pools within
the cell or that inhibit zinc binding to a restricted class
of protein, may be more effective in this regard.
Among the critical limitations in advancing our
understanding of the role of zinc in tumor immunology
are: a) availability of quantitative zinc sensors (e.g. ratio-
metric fluorophores, genetically encoded and easily used
detectors, etc) for cellular and organ physiology; b)
improved analytical tools to approach the zinc proteome
in earnest and in a more high throughput conducive
fashion; c) needed progress in biomarkers of zinc defi-
ciency and/or imaging of zinc in medicine in addition to
current rather difficult to interpret measurements of
total zinc in various biological compartments; d) more
complete information on polymorphisms in various zinc
transporters, importers and binding proteins; and e)
methods of targeting specific subcellular pools of zinc. It
is quite likely that alterations in zinc homeostasis may
be a contributing factor in genetic alternations (ZNT,
ZIP, metallothionein, etc) or environmental causes
(nutritional status, exposure to zinc, microbial control)
playing a role in the genesis and/or maintenance of can-
cer. Its role in HMGB1 and RAGE signaling in cancer
has not been fully explored [173-175]. As such, a
rational approach towards zinc supplementation and
modulation may ultimately emerge in the context of
preventing or treating immunologic and oncologic
disorders.
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